A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
|
Non-Small Cell Lung Cancer Brain Neoplasms |
Drug: bevacizumab Drug: First-Line Chemotherapy Agents Drug: Second-Line Chemotherapy Agents |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer |
- Percentage of Participants With Symptomatic National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (NCI CTCAE) Grade ≥2 Central Nervous System (CNS) Hemorrhage [ Time Frame: From the first administration of bevacizumab until 60 days after discontinuation of bevacizumab treatment was reported (up to 2 years) ] [ Designated as safety issue: Yes ]
The percentage of participants with symptomatic NCI CTCAE Grade ≥ 2 CNS hemorrhage, defined as the presence of clinical symptoms determined by the investigator to be directly referable to a Grade ≥ 2 CNS hemorrhage.
Grade 1: Asymptomatic, radiographic findings only Grade 2: Medical intervention indicated Grade 3: Ventriculostomy, intracranial pressure (ICP) monitoring, intraventricular thrombolysis, or operative intervention indicated Grade 4: Life-threatening consequences; neurologic deficit or disability Grade 5: Death
- Overall Survival (OS) in First-line Setting [ Time Frame: Time from enrollment to death from any cause (up to 2 years) ] [ Designated as safety issue: No ]To assess overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.
- Number of Participants With Overall Survival (OS) in First-line Setting [1−Year or More Survival] [ Time Frame: Time from enrollment to death from any cause (up to 2 years) ] [ Designated as safety issue: No ]Number of Participants with overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.
- OS in First-line and Second-line Settings [ Time Frame: Time from enrollment to death from any cause (up to 2 years) ] [ Designated as safety issue: No ]To assess overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.
- Number of Participants With OS in First-line and Second-line Settings [1−Year or More Survival] [ Time Frame: Time from enrollment to death from any cause (up to 2 years) ] [ Designated as safety issue: No ]To assess the number of participants with overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.
- Number of Participants With Selected Adverse Events [ Time Frame: From start of bevacizumab treatment to 60 days following discontinuation of bevacizumab (up to 2 years) ] [ Designated as safety issue: No ]
Number of participants with selected adverse events (all grades based on NCI CTCAE) included any grade CNS hemorrhage, any grade pulmonary hemorrhage, any grade gastrointestinal (GI) perforation, Grade ≥ 2 arterial thromboembolic event, Grade ≥ 2 left ventricular systolic dysfunction, Grade ≥ 3 non-CNS non-pulmonary hemorrhage, Grade ≥ 3 proteinuria, Grade ≥ 3 proteinuria, Grade ≥ 3 hypertension, any serious adverse event*, and any adverse event leading to study treatment discontinuation.
*For serious adverse events, please see Adverse Event Reporting Section.
| Enrollment: | 115 |
| Study Start Date: | March 2006 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: bevacizumab |
Drug: bevacizumab
15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be < 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
Other Name: Avastin
Drug: First-Line Chemotherapy Agents
Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily. All agents were dosed and administered per institutional standards using the respective package insert as a guideline. Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued. All agents were dosed and administered per institutional standards using the respective package insert as a guideline. |
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed informed consent
- Histologically or cytologically confirmed NSCLC except for squamous cell carcinoma
- Treated brain metastases without evidence of progression or hemorrhage after treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period
- Appropriateness for first- or second-line systemic therapy for advanced NSCLC
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Age ≥ 18 years
- For women of childbearing potential and sexually active males, use of an accepted and effective method of contraception (e.g., hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study
Exclusion Criteria:
- Brain biopsy/neurosurgical procedure performed within 3 months prior to Day 1
- Progressive neurologic symptoms
- Active malignancy other than lung cancer
- Current, recent, or planned participation in an experimental drug study
- Prior treatment with an investigational or marketed agent that acts by anti-angiogenesis mechanisms
- Gross hemoptysis within 3 months prior to Day 1
- Inadequately controlled hypertension
- Unstable angina or New York Heart Association Grade II or greater congestive heart failure (CHF)
- Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1
- Myocardial infarction within 6 months prior to Day 1
- Stroke within 6 months prior to Day 1
- Active symptomatic peripheral vascular disease within 6 months prior to Day 1
- History of significant vascular disease
- Evidence of bleeding diathesis or coagulopathy
- Known hypersensitivity to any components of bevacizumab
- Inadequate organ function
- Serious non-healing wound, ulcer, or bone fracture
- Urine protein/creatinine (UPC) ratio of ≥ 1.0
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study
- Pregnancy or lactation
- Known evidence of disseminated intravascular coagulation (DIC)
- Active infection or fever > 38.5°C within 3 days prior to Day 1
- Any other medical condition (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00312728
| Study Director: | David Karlin, M.D. | Genentech, Inc. |
More Information
| Responsible Party: | Jane Huang, M.D., Study Director, Genentech, Inc. |
| ClinicalTrials.gov Identifier: | NCT00312728 History of Changes |
| Other Study ID Numbers: | AVF3752g |
| Study First Received: | April 7, 2006 |
| Results First Received: | March 18, 2011 |
| Last Updated: | August 3, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Genentech, Inc.:
|
Brain Cancer Brain Metastases Avastin |
NSCLC Lung Cancer PASSPORT |
Additional relevant MeSH terms:
|
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Neoplasm Metastasis Brain Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Neoplastic Processes |
Pathologic Processes Central Nervous System Neoplasms Nervous System Neoplasms Brain Diseases Central Nervous System Diseases Nervous System Diseases Bevacizumab Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents |
ClinicalTrials.gov processed this record on September 28, 2016